Drug intelligence / Profile preview

tovaxin

Development stage: Phase 2
Lead developer: Zevra Therapeutics
Modality: Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Tovaxin is an investigational therapeutic vaccine developed for the treatment of multiple sclerosis. It is a form of autologous T cell vaccine, meaning it is created from the patient’s own myelin-reactive T cells, which are expanded and then attenuated ex vivo before being reintroduced to induce immune tolerance. The primary mechanism involves modulating the immune response against myelin antigens implicated in multiple sclerosis pathogenesis. Tovaxin was primarily developed by Opexa Therapeutics for relapsing forms of multiple sclerosis.

Brand names: Tcelna
Other names: TovaxinTcelna

Beyond the preview

Go deeper on tovaxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tovaxin.

Explore the full profile